AXL and neoplasm: In this regard, Holland and colleagues [68] generated and characterized a highly selective small-molecule inhibitor (R428, Rigel Pharmaceuticals) that potently blocks the catalytic activity of AXL and AXL-dependent biological functions, including tumor cell invasion and angiogenesis in tumor mouse models.